Treatment∆
| IL-6a
| IFN-γb
| LSZc
|
---|
Normal control | 74.47±15.12 | 246.44±32.62 | 6.31±0.98 |
Cy(100 mg/kg) | 40.56±9.76##
| 80.96±10.83##
| 3.87±0.67##
|
ZYQL-A(100 mg/kg) | 81.60±24.82 | 262.52±55.74 | 7.03±1.05 |
ZYQL-B(200 mg/kg) | 89.04±15.57 | 277.61±68.42 | 7.67±1.12##
|
ZYQL-C(400 mg/kg) | 86.98±11.97 | 256.81±46.83 | 7.30±0.91#
|
ZYQL-A(100 mg/kg)+Cy | 80.54±11.37**
| 185.34±28.81**
| 4.57±0.85*
|
ZYQL-B(200 mg/kg)+Cy | 101.74±30.72**
| 231.84±58.32**
| 8.87±0.76**
|
ZYQL-C(400 mg/kg)+Cy | 79.24±16.66**
| 230.16±31.63**
| 7.98±0.98**
|
- Data is expressed as the mean±SD (n = 10).
-
a pg/mL.
-
b pg/mL.
-
c μg/mL.
-
## Significant difference at p<0.01 levels compared with normal control group.
-
# Significant difference at p<0.05 levels compared with normal control group.
-
** Significant difference at p<0.01 levels compared with Cy-treated group.
-
* Significant difference at p<0.05 levels compared with Cy-treated group.
-
∆ Significant difference at p<0.05 (fIFN-γ = 3.692, fLSZ = 3.845) levels compared between cyclophosphamide- untreated groups and cyclophosphamide-treated groups (two-way ANOVA followed by LSD’s test).